Tempus Contributes De-Identified Cancer Data to Planned Data Enclave

This is a first of its kind contribution to NCI’s planned Data Enclave and will support the NCI’s mission of advancing cancer research by learning from each individual with cancer.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Thursday, March 14, 2024
Information
Tags: 
Technology, Research, Software, Health, General Health, Data Management, Science, Artificial Intelligence, Oncology, Health informatics, NCI, Informatics, TCGA, Learning, Associate, Intelligence, Patient, API, Knowledge, National Cancer Institute, Information technology, Cancer, Doctor of Philosophy, MD, NIH, Medicine, Neoplasm, Bangladesh Technical Education Board, Data, The Cancer Genome Atlas, Medical imaging
Geotags: 
UNITED STATES, NORTH AMERICA, ILLINOIS
Organisation: 
TEMPUS
Summary
Key Points: 
  • This is a first of its kind contribution to NCI’s planned Data Enclave and will support the NCI’s mission of advancing cancer research by learning from each individual with cancer.
  • These de-identified data files with associated limited clinical information are derived from advanced-stage cancer patients sequenced with Tempus’ signature xT assay.
  • All summary level results returned to the users by the NCI Data Enclave will be openly accessible to the full cancer research community.
  • “This data will greatly expand the genomic data resources available to the cancer research community.


Tempus, a leader in artificial intelligence and precision medicine, today announced a generous data contribution of de-identified tumor profiles with limited associated clinical information from more than 3,000 cancer diagnoses to the National Cancer Institute (NCI), part of the National Institutes of Health (NIH). This is a first of its kind contribution to NCI’s planned Data Enclave and will support the NCI’s mission of advancing cancer research by learning from each individual with cancer.

These de-identified data files with associated limited clinical information are derived from advanced-stage cancer patients sequenced with Tempus’ signature xT assay. The data contribution will build on sequencing results generated through The Cancer Genome Atlas (TCGA).

The tumor data and associated limited clinical information will be available for researchers to query through the NCI Data Enclave, which will securely host data files, including genomic sequencing, that were attained in clinical settings. Users will interact indirectly with the NCI Data Enclave through an Application Programming Interface (API), which will receive queries from users and return cohort level summary results. All summary level results returned to the users by the NCI Data Enclave will be openly accessible to the full cancer research community.

“A core pillar of Tempus’ mission is our commitment to furthering cancer research, leveraging our vast library of multimodal data in order to improve patient care now and in the future,” said Ezra Cohen, MD, Chief Medical Officer of Oncology at Tempus. “A dataset of this size is an invaluable tool for any research entity, and we hope that making it accessible through the National Cancer Institute will help to accelerate researchers’ work in a meaningful way.”

“Data contributions allow the cancer research community to continue to learn and advance our knowledge in cancer thereby fulfilling NCI’s mission,” said Jill Barnholtz-Sloan, PhD, Associate Director for the Informatics and Data Science Program in NCI’s Center for Biomedical Informatics and Information Technology and Senior Investigator in the NCI Division of Cancer Epidemiology and Genetics. “This data will greatly expand the genomic data resources available to the cancer research community. Datasets of this magnitude are desperately needed to have the statistical power to study rare cancers and rare subtypes of common cancers.”

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

Copyright: 
Copyright Business Wire 2024